Implantable cardioverter defibrillator therapy in patients with arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, or no structural heart disease

https://doi.org/10.1016/0002-8703(94)90103-1Get rights and content

Abstract

Recent technical developments in implantable cardioverter defibrillator (ICD) systems and reduced operative mortality and morbidity rates associated with ICD implantation have expanded the indications for ICD treatment of ventricular tachyarrhythmias. This review summarizes data regarding ICD therapy in patients with arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, and idiopathic ventricular fibrillation and presents preliminary concepts for identification of patients who will benefit more from ICD therapy than from pharmacologic and other nonpharmacologic approaches. Recent studies suggest that ICD therapy may improve long-term prognosis by reliably terminating recurrences of life-threatening arrhythmias. Appropriate ICD therapies during mean follow-up periods of 12 to 36 months occurred in 30% of patients with idiopathic ventricular fibrillation to 50% of patients with arrhythmogenic right ventricular cardiomyopathy and long QT syndrome. At present no strict recommendations can be given for ICD implantation in these patients. However, at least in cardiac arrest survivors in whom the clinical arrhythmia is not reproducibly inducible during electrophysiologic study, ICD therapy appears to be superior to other treatment options with regard to long-term survival and thus should be considered as a first-line treatment. We are hopeful that continued study of long-term follow-up with and without ICD treatment and improved risk stratification will lead to better criteria for selection of treatment options.

References (29)

  • C Blömstrom-Lundqvist et al.

    A long-term follow up of 15 patients with arrhythmogenic right ventricular dysplasia

    Eur Heart J

    (1987)
  • FI Marcus et al.

    Long-term follow-up in patients with arrhythmogenic right ventricular disease

    Eur Heart J

    (1989)
  • G Thiene et al.

    Right ventricular cardiomyopathy and sudden death in young people

    N Engl J Med

    (1988)
  • T Wichter et al.

    Long-term follow-up in patients with arrhythmogenic right ventricular disease [Abstract]

    Circulation

    (1992)
  • Cited by (75)

    • Long-term right ventricular implantable cardioverter-defibrillator lead performance in arrhythmogenic right ventricular cardiomyopathy

      2016, Heart Rhythm
      Citation Excerpt :

      Therefore, long-term optimum lead performance is imperative to patient safety5,6 and is of particular importance in patients with progressive diseases such as arrhythmogenic right ventricular cardiomyopathy (ARVC) because the majority of these patients will undergo ICD placement at a relatively young age. Progressive replacement of muscle with fibrofatty deposits may result in loss of R-wave amplitude and suboptimal sensing.7 Furthermore, ARVC patients are often diagnosed when they are young adults, with a longer course of disease progression compared to other conditions for which ICDs are implanted at later stages in life.

    • Implantable Cardioverter Defibrillator in Arrhythmogenic Cardiomyopathy

      2011, Cardiac Electrophysiology Clinics
      Citation Excerpt :

      The first studies aimed at defining the clinical results of ICD implantation were conducted on small cohorts of AC patients.19–21 In 1994 Breithardt and colleagues19 reported 18 patients with AC who received an ICD because of drug refractory VT or VF, or previous cardiac arrest without reproducible induction of VT or VF. Only the initial patient received an epicardial lead system, whereas in the subsequent 17 patients a transvenous approach was used.

    • Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Risk Stratification and Therapy

      2008, Progress in Cardiovascular Diseases
      Citation Excerpt :

      However, EPS may provide useful information if the spontaneous VT cycle length was not recorded. In summary, the available data suggest that young age (<35 years), prior cardiac arrest, fast and poorly tolerated VT with different morphologies, syncope, severe right ventricular dysfunction, heart failure with left ventricular involvement, familial occurrence of juvenile sudden death are the major determinants in predicting sudden death and worse outcome.4-8,16-24,31,32 In patients with ARVC/D, vigorous or competitive sport activities should be restricted to decrease the rate of structural and/or functional progression of the disease as well as the risk of arrhythmic death.

    • Arrhythmogenic cardiomyopathy

      2019, Zdravniski Vestnik
    View all citing articles on Scopus
    View full text